Minerva Neurosciences’ (NERV) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Saturday, February 22nd. They issued a “sell” rating for the company.

Minerva Neurosciences Stock Down 2.2 %

Shares of NASDAQ:NERV opened at $1.75 on Wednesday. Minerva Neurosciences has a 52-week low of $1.71 and a 52-week high of $3.69. The stock has a market cap of $12.24 million, a P/E ratio of -3.98 and a beta of 0.12. The business has a fifty day moving average of $2.16 and a two-hundred day moving average of $2.39.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.49. On average, equities analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC increased its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. 34.56% of the stock is owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.